Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.41 |
| ▸ | JAK3 | P52333 | 7/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | TTK | P33981 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41177 | 0.86 | LRRK2 (0.46) | JAK2JAK3JAK1LRRK2PTK2 | |
| SCHEMBL42118 | 0.81 | SRC (0.42) | JAK2JAK1TTKSRC | |
| SCHEMBL41008 | 0.81 | LRRK2 (0.44) | JAK2LRRK2TTKSRC | |
| SCHEMBL613379 | 0.81 | LRRK2 (0.47) | JAK2JAK3LRRK2PTK2TTK | |
| SCHEMBL41482 | 0.81 | LRRK2 (0.46) | JAK2LRRK2TTKSRC | |
| SCHEMBL42778 | 0.80 | LRRK2 (0.41) | JAK2LRRK2TTKTYK2SRC | |
| SCHEMBL41398 | 0.80 | LRRK2 (0.41) | JAK2LRRK2TTKSRC | |
| SCHEMBL612376 | 0.80 | SRC (0.46) | JAK2JAK3LRRK2PTK2TTK | |
| SCHEMBL41292 | 0.80 | LRRK2 (0.49) | JAK2JAK3LRRK2PTK2TTK | |
| SCHEMBL41596 | 0.80 | LRRK2 (0.43) | JAK2JAK3LRRK2PTK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | claimed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | claimed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | JAK2 283/4885JAK3 824/4885JAK1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.